Idelalisib monotherapy and durable responses in patients with relapsed or refractory small lymphocytic lymphoma (SLL)

被引：0
|
作者：
Gopal, A. [1 ]
Davies, A. J. [2 ]
Flinn, I. [3 ]
Ghia, P. [4 ,5 ]
Goy, A. [6 ]
Salles, G. [7 ]
Abella, S. [8 ]
Philip, B. [8 ]
Sorenson, B. [8 ]
Wagner-Johnston, N. [9 ]
机构：
[1] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA
[2] Univ Southampton, Canc Sci Unit, Salisbury, Wilts, England
[3] Sarah Cannon Res Inst, Hematol Malignancies Res Program, Nashville, TN USA
[4] Univ Vita Salute San Raffaele, Milan, Italy
[5] IRCCS Ist Sci San Raffaele, Milan, Italy
[6] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[7] Univ Lyon 1, Hosp Civils Lyon, Pierre Benite, France
[8] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[9] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2016年 / 173卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
245
引用
下载
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [41] Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Hillmen, Peter
    Brown, Jennifer R.
    Byrd, John C.
    Eichhorst, Barbara F.
    Lamanna, Nicole
    O'Brien, Susan M.
    Qiu, Lugui
    Salmi, Tommi
    Hilger, James
    Huang, Jane
    Tam, Constantine S.
    BLOOD, 2019, 134
  • [42] A Systematic Literature Review of Utility Estimates for Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
    Yucel, E.
    Hartley, L.
    Bell, J.
    Wolowacz, S.
    Kamgar, F.
    Hawe, E.
    VALUE IN HEALTH, 2022, 25 (12) : S395 - S395
  • [43] The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study
    O'Brien, Susan
    Burger, Jan A.
    Blum, Kristie A.
    Furman, Richard R.
    Coutre, Steven E.
    Sharman, Jeff
    Flinn, Ian W.
    Grant, Barbara
    Heerema, Nyla A.
    Johnson, Amy J.
    Navarro, Tasheda
    Holmgren, Eric
    Hedrick, Eric
    Byrd, John C.
    BLOOD, 2011, 118 (21) : 449 - 450
  • [44] ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete-response rate and durable disease control.
    Seymour, John Francis
    Davids, Matthew Steven
    Pagel, John M.
    Kahl, Brad S.
    Wierda, William G.
    Puvvada, Soham
    Gerecitano, John F.
    Kipps, Thomas J.
    Anderson, Mary Ann
    Huang, David C. S.
    Rudersdorf, Nikita
    Gressick, Lori A.
    Montalvo, Nicholas P.
    Yang, Jianning
    Zhu, Ming
    Dunbar, Martin
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod
    Roberts, Andrew Warwick
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Romidepsin Induces Durable Responses in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)
    Pro, Barbara
    Horwitz, Steven M.
    Prince, H. Miles
    Foss, Francine M.
    Sokol, Lubomir
    Greenwood, Matthew
    Caballero, Dolores
    Morschhauser, Franck
    Wilhelm, Martin
    Pinter-Brown, Lauren
    Iyer, Swaminathan Padmanabhan
    Malignancies, Hematological
    Shustov, Andrei R.
    Wolfson, Julie
    Balser, Barbara E.
    Coiffier, Bertrand
    BLOOD, 2014, 124 (21)
  • [46] Update on a phase 2 study of idelalisib in combination with rituximab in treatment-naive patients ≥65 years with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
    Dubowy, R.
    O'Brien, S.
    Lamanna, N.
    Kipps, T.
    Flinn, I.
    Zelenetz, A.
    Burger, J.
    Holes, L.
    Cho, Y.
    Coutre, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 57 - 57
  • [47] Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naive Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
    O'Brien, Susan
    Lamanna, Nicole
    Kipps, Thomas J.
    Flinn, Ian W.
    Zelenetz, Andrew D.
    Burger, Jan A.
    Holes, Leanne M.
    Cho, Yoonjin
    Dubowy, Ronald L.
    Coutre, Steven E.
    BLOOD, 2014, 124 (21)
  • [48] Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies
    Rainone, Michael
    Siddiqi, Tanya
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2022, 17 (01) : 39 - 45
  • [49] ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
    Hillmen, Peter
    Brown, Jennifer R.
    Eichhorst, Barbara F.
    Lamanna, Nicole
    O'Brien, Susan M.
    Qiu, Lugui
    Salmi, Tommi
    Hilger, James
    Wu, Kenneth
    Cohen, Aileen
    Huang, Jane
    Tam, Constantine S.
    FUTURE ONCOLOGY, 2020, 16 (10) : 517 - 523
  • [50] Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis
    Xu, Wei
    Yang, Shenmiao
    Zhou, Keshu
    Pan, Ling
    Li, Zengjun
    Gao, Sujun
    Zhou, Daobin
    Hu, Jianda
    Feng, Ru
    Huang, Haiwen
    Wang, Tingyu
    Li, Dengju
    Ji, Meng
    Guo, Haiyi
    Zhao, Xia
    Wu, Binghao
    Yu, Yiling
    Wang, Yu
    Huang, Jane
    Novotny, William
    Li, Jianyong
    LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 712 - 716
12345